abrdn Life Sciences Investors (NYSE:HQL) Stock Breaks Above 200 Day Moving Average - Should You Sell?

Key Points

• HQL shares moved above their 200-day moving average, reaching $18.31 and last trading at $18.28, compared with a 200-day average of $18.21.
• The fund paid a quarterly dividend of $0.62 per share, equivalent to $2.48 annually and a 13.6% dividend yield.
• Institutional investors owned 32.21% of HQL, with several firms increasing their positions or initiating new stakes during the second and third quarters.

Shares of abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $18.21 and traded as high as $18.31. abrdn Life Sciences Investors shares last traded at $18.28, with a volume of 92,971 shares traded.

abrdn Life Sciences Investors Price Performance

The business has a 50-day moving average of $19.24 and a 200 day moving average of $18.21.

abrdn Life Sciences Investors Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 13.6%. The ex-dividend date of this dividend was Monday, August 24th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Ashton Thomas Securities LLC purchased a new position in shares of abrdn Life Sciences Investors in the 3rd quarter worth $242,000. Flagship Harbor Advisors LLC increased its holdings in shares of abrdn Life Sciences Investors by 4.1% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company's stock worth $7,805,000 after buying an additional 16,601 shares during the last quarter. Wedbush Securities Inc. increased its holdings in shares of abrdn Life Sciences Investors by 21.1% in the 3rd quarter. Wedbush Securities Inc. now owns 19,335 shares of the company's stock worth $362,000 after buying an additional 3,375 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of abrdn Life Sciences Investors by 111.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 30,011 shares of the company's stock valued at $601,000 after buying an additional 15,805 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of abrdn Life Sciences Investors during the 2nd quarter valued at about $287,000. 32.21% of the stock is currently owned by institutional investors.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.

Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.

The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla's investment management activities into abrdn.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.